LumiraDx News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.12.23	LumiraDx Agrees To Sell Point-of-Care Tech Platform To Roche (RTTNews)
30.06.23	LumiraDx Submits Medical Device Application To FDA For COVID Ultra Test (RTTNews)
14.11.22	LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test (PR Newswire)
14.11.22	Mit HbA1c-Test erweitert LumiraDx erneut sein Mikrofluidik-Point-of-Care-Diagnostik-Portfolio (GlobeNewswire)
14.11.22	LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test (GlobeNewswire)
09.11.22	LumiraDx Reports Third Quarter 2022 Results (GlobeNewswire)
12.10.22	LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry (GlobeNewswire)
22.09.22	LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance (GlobeNewswire)
21.07.22	LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement (PR Newswire)
19.07.22	LumiraDx Announces Proposed Public Offering of Common Shares (PR Newswire)
18.07.22	Pre-market Movers: ILAG, USEA, TSLX, EVTL, ITHX… (RTTNews)
09.06.22	LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System (PR Newswire)
08.06.22	LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete (PR Newswire)
02.06.22	LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test (PR Newswire)
26.05.22	LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform (PR Newswire)
20.05.22	LumiraDx's SARS-CoV-2 Ag Test Receives WHO Emergency Use Listing (RTTNews)
20.05.22	LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test (PR Newswire)
19.05.22	LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking (PR Newswire)
11.05.22	LumiraDx Reports First Quarter 2022 Results (PR Newswire)
29.04.22	LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11 (PR Newswire)
10.03.22	LumiraDx Reports Fourth Quarter and Full Year 2021 Results (PR Newswire)
03.03.22	LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10 (PR Newswire)
01.03.22	LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering (PR Newswire)
14.01.22	LumiraDx: In-house SARS-CoV-2 Antigen Test Detects Omicron Variant (RTTNews)
14.01.22	LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant (PR Newswire)
11.01.22	LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test (PR Newswire)
11.01.22	LumiraDx CRP Test Achieves CE Marking (PR Newswire)
23.12.21	LumiraDx Gets CE Marking For New SARS-CoV-2 And Flu A/B Antigen Test Kit (RTTNews)
23.12.21	LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking (PR Newswire)
15.12.21	LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete (PR Newswire)
01.12.21	FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions (PR Newswire)
10.11.21	LumiraDx Reports Third Quarter 2021 Financial Results (PR Newswire)
02.11.21	LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10 (PR Newswire)
01.11.21	LumiraDx Announces the Intended Use for its FDA EUA Authorized High Sensitivity COVID-19 Antigen Test has been Expanded to Include Testing of Asymptomatic Individuals (PR Newswire)
22.10.21	Pre-market Movers: PHUN, CRTD, MTCR, DWAC, SNAP… (RTTNews)
20.10.21	LumiraDx receives approval for its COVID-19 Antigen Test for use in India (PR Newswire)
15.10.21	LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu LumiraDx Limited Registered Shs -A-

Aktien Top/Flop

LumiraDx Peer Group Nachrichten

Meistgelesene Nachrichten